STOCK TITAN

Protara Therapeutics Inc - TARA STOCK NEWS

Welcome to our dedicated news page for Protara Therapeutics (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Protara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Protara Therapeutics's position in the market.

Rhea-AI Summary
Protara Therapeutics, Inc. announces preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS and expects data from ADVANCED-2 trial in 2024. The company has $66M in cash to fund operations until Q2 2025. Financial results show increased R&D expenses but reduced net loss compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
earnings
-
Rhea-AI Summary
Protara Therapeutics, Inc. (TARA) to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.45%
Tags
conferences
-
Rhea-AI Summary
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in two upcoming investor conferences, including the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company will hold fireside chats at these events, with a live webcast available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
conferences
Rhea-AI Summary
Protara Therapeutics, a clinical-stage company (Nasdaq: TARA), released encouraging data from the Phase 1a dose-escalation component of its ADVANCED-1 clinical trial of TARA-002 for high-grade non-muscle invasive bladder cancer. The study showed favorable tolerability, anti-tumor activity, and high-grade recurrence-free survival. The company also announced the commencement of the ADVANCED-2 trial for further evaluation of TARA-002.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
clinical trial
-
Rhea-AI Summary
Protara Therapeutics announces progress in clinical trials for TARA-002, with preliminary results expected in 1H24. The company also initiates a Phase 2 trial for TARA-002 in Lymphatic Malformations. Cash, cash equivalents, and investments as of September 30, 2023, are $74M, expected to fund operations into Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.57%
Tags
earnings
-
Rhea-AI Summary
Protara Therapeutics has announced the initiation of the Phase 2 STARBORN-1 trial for TARA-002, an investigational cell-based immunopotentiator, in pediatric patients with lymphatic malformations (LMs). The trial aims to evaluate the safety and efficacy of TARA-002 in treating macrocystic and mixed cystic LMs. TARA-002 is based on the immunopotentiator OK-432, which has been approved in Japan and Taiwan for LMs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
clinical trial
Rhea-AI Summary
Protara Therapeutics progresses dosing in ADVANCED-1EXP and ADVANCED-2 trials for TARA-002 in NMIBC patients with CIS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
clinical trial
-
Rhea-AI Summary
Protara Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
conferences
-
Rhea-AI Summary
Protara Therapeutics, Inc. (TARA) announced positive preliminary results from the Phase 1a dose-escalation component of the ADVANCED-1 clinical trial of TARA-002, its investigational cell-based therapy, for the treatment of patients with high-grade NMIBC. The clinical data indicate that TARA-002 was generally well tolerated and anti-tumor activity was observed, including tumor regression in all three evaluable patients with carcinoma in situ (CIS), including one heavily pre-treated Bacillus Calmette-Guérin (BCG)-unresponsive patient who achieved a complete response (CR). The company plans to commence dosing in ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS in 4Q23. In addition, Protara plans to initiate Phase 2 trial of TARA-002 in Lymphatic Malformations in 4Q23. The company has cash, cash equivalents, and investments of $80M as of June 30, 2023, expected to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
clinical trial
Protara Therapeutics Inc

Nasdaq:TARA

TARA Rankings

TARA Stock Data

45.74M
7.10M
16.59%
38.93%
0.69%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
New York

About TARA

protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.